Literature DB >> 17950993

Isolation of CD24(high) and CD24(low/-) cells from MCF-7: CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7.

Hee Joung Kim1, Jong Bin Kim, Kyung-Min Lee, Incheol Shin, Wonshik Han, Eunyoung Ko, Ji-Yeon Bae, Dong-Young Noh.   

Abstract

CD24 has been reported to have a role in metastasis of several malignancies including breast cancer. We investigated the effect of CD24 expression on biologic features in human breast cancer cells, and found that CD24 expression is associated with more rapid growth and enhanced ability of adhesion and invasion in MCF-7. The proportion of cells was higher in synthetic phase and lower in arrestic phase for CD24(high) than for CD24(low/-) cells. Cyclin D1 and p27 had stronger expressions in CD24(low/-) cells than CD24(high) cells. These suggested one possible pathway for CD24 effect on proliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17950993     DOI: 10.1016/j.canlet.2007.08.025

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  Direct measurements on CD24-mediated rolling of human breast cancer MCF-7 cells on E-selectin.

Authors:  Ja Hye Myung; Khyati A Gajjar; Ryan M Pearson; Cari A Launiere; David T Eddington; Seungpyo Hong
Journal:  Anal Chem       Date:  2011-01-05       Impact factor: 6.986

2.  Identification, functional characterization, and pathobiological significance of GLI1 isoforms in human cancers.

Authors:  Richard L Carpenter; Hui-Wen Lo
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

3.  Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.

Authors:  Te Liu; Fuhui Xu; Xiling Du; Dongmei Lai; Tianjin Liu; Yarui Zhao; Qin Huang; Lizhen Jiang; Wenbin Huang; Weiwei Cheng; Zhixue Liu
Journal:  Mol Cell Biochem       Date:  2010-03-12       Impact factor: 3.396

4.  The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.

Authors:  Alexandra Giatromanolaki; Efthimios Sivridis; Aliki Fiska; Michael I Koukourakis
Journal:  Med Oncol       Date:  2010-04-20       Impact factor: 3.064

5.  The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo.

Authors:  Shiran Shapira; Dina Kazanov; Samuel Weisblatt; Alex Starr; Nadir Arber; Sarah Kraus
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

6.  A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion.

Authors:  Hui-Wen Lo; Hu Zhu; Xinyu Cao; Amy Aldrich; Francis Ali-Osman
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

7.  Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.

Authors:  Germana Rappa; Aurelio Lorico
Journal:  Exp Cell Res       Date:  2010-01-11       Impact factor: 3.905

Review 8.  Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes.

Authors:  Fernando Schmitt; Sara Ricardo; André Filipe Vieira; Maria Rita Dionísio; Joana Paredes
Journal:  Virchows Arch       Date:  2012-05-05       Impact factor: 4.064

9.  Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines.

Authors:  Matthew J Meyer; Jodie M Fleming; Mustapha A Ali; Mitchell W Pesesky; Erika Ginsburg; Barbara K Vonderhaar
Journal:  Breast Cancer Res       Date:  2009-11-11       Impact factor: 6.466

10.  Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231.

Authors:  Arturo Aguilar-Rojas; Maira Huerta-Reyes; Guadalupe Maya-Núñez; Fabián Arechavaleta-Velásco; P Michael Conn; Alfredo Ulloa-Aguirre; Jesús Valdés
Journal:  BMC Cancer       Date:  2012-11-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.